Bioporto ASOCSE:BIOPOR -2.21%69 OCF Margin % is -134.88% as of Dec. 2025. GuruFocus rates OCSE:BIOPOR with a GF Score™ of 69/100 and a GF Value™ of kr1.24 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 84.73% on this metric.
The historical rank and industry rank for Bioporto AS's OCF Margin % or its related term are showing as below:
OCSE:BIOPOR'
s OCF Margin % Range Over the Past 10 Years
Min: -266.25 Med: -180.16 Max: -94.88
Current: -191.29
During the past 13 years, the highest OCF Margin % of Bioporto AS was -94.88%. The lowest was -266.25%. And the median was -180.16%.
OCSE:BIOPOR's OCF Margin % is ranked worse than 84.73% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.67
vs OCSE:BIOPOR: -191.29
Bioporto AS OCF Margin % Related Terms
Bioporto AS OCF Margin % Historical Data
* Premium members only.
The historical data trend for Bioporto AS's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:BIOPOR vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Bioporto AS's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bioporto AS's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (OCSE:BIOPOR) has a OCF Margin % of -134.88% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #172 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 84.7%.
Is Bioporto AS's OCF Margin % too high?
Bioporto AS's current OCF Margin % is -134.88%. Based on the distribution chart, Bioporto AS ranks #172 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bioporto AS has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #172 out of 203 companies for OCF Margin %. This places Bioporto AS in the lower half of its industry. The industry median OCF Margin % is 4.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.67, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current OCF Margin % is -134.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Based on GuruFocus' analysis, Bioporto AS (OCSE:BIOPOR) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.24, compared to a current price of kr1.11 — trading 10.9% below its estimated fair value. The current OCF Margin % is -134.88%. Bioporto AS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bioporto AS (OCSE:BIOPOR), the current OCF Margin % is -134.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of kr1.11 is trading 10.9% below its estimated GF Value™ of kr1.24.
GuruFocus considers Bioporto AS to be Modestly Undervalued.
Key valuation signals for OCSE:BIOPOR:
OCF Margin %: -134.88%
GF Value™: kr1.24 vs. price of kr1.11 (10.9% below fair value)
No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score
Get the complete analysis for OCSE:BIOPOR
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:BIOPOR has been successfully added to your 
